Will Teva's Deal With FTC Change Future Patent Litigation Settlements?

 
• By Brenda Sandburg

Settlement reflects existing landscape in which companies are avoiding no-authorized generic commitments, and may harbinger FTC's shift to other issues.

Silhouette woman to jump over obstacles over precipice between rocky mountains A Step to success at background sunset pastel.

More from Generics

More from Biosimilars & Generics